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Abstract
Chemotherapy continues to have a major impact on reducing the burden of disease caused
by trypanosomatids. Unfortunately though, the mode-of-action (MoA) of antitrypanosomal
drugs typically remains unclear or only partially characterised. This is the case for four of
five current drugs used to treat Human African Trypanosomiasis (HAT); eflornithine is a spe-
cific inhibitor of ornithine decarboxylase. Here, we used a panel of T. brucei cellular assays
to probe the MoA of the current HAT drugs. The assays included DNA-staining followed by
microscopy and quantitative image analysis, or flow cytometry; terminal dUTP nick end
labelling to monitor mitochondrial (kinetoplast) DNA replication; antibody-based detection
of sites of nuclear DNA damage; and fluorescent dye-staining of mitochondria or lyso-
somes. We found that melarsoprol inhibited mitosis; nifurtimox reduced mitochondrial
protein abundance; pentamidine triggered progressive loss of kinetoplast DNA and dis-
ruption of mitochondrial membrane potential; and suramin inhibited cytokinesis. Thus,
current antitrypanosomal drugs perturb distinct and specific cellular compartments, struc-
tures or cell cycle phases. Further exploiting the findings, we show that putative mitogen-
activated protein-kinases contribute to the melarsoprol-induced mitotic defect, reminis-
cent of the mitotic arrest associated signalling cascade triggered by arsenicals in mam-
malian cells, used to treat leukaemia. Thus, cytology-based profiling can rapidly yield
novel insight into antitrypanosomal drug MoA.
Author summary
African trypanosomes cause devastating and lethal diseases in humans and livestock.
These parasites are transmitted among mammals by tsetse flies and circulate and grow
in blood and tissue fluids. There are several drugs available to treat patients but, despite
their use for many decades, we know relatively little about how they work. We reasoned
that exposure of trypanosomes to each drug, followed by microscopic examination of
cellular structures, would reveal the major cellular compartments, structures or growth
phases affected. For example, we examined two major DNA structures, and cellular
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compartments known as mitochondria. We found that two drugs thought to act in mito-
chondria did indeed disrupt this compartment, but in completely different ways. Another
drug stopped cell growth at a specific point in the cycle. An arsenic-based drug, related to
anti-leukaemia drugs, perturbed the nuclear DNA division cycle, indicating that arsenicals
may kill parasites and cancer cells by similar mechanisms. Thus, the ‘chemical-biology’
profiles we observe illuminate distinct killing mechanisms. A similar approach can now
be used to assess new drugs, and the insights may help to develop improved anti-parasite
therapies.
Introduction
Chemotherapy is central to the control of the neglected tropical diseases caused by African try-
panosomes (Trypanosoma brucei spp), South American trypanosomes (Trypanosoma cruzi)
and Leishmania spp; the related kinetoplastid parasites [1]. The current drugs suffer problems
with complex administration, efficacy, toxicity and resistance [2]. There are a small number of
drugs in clinical trials for these diseases but there remains a desperate need for new and
improved drugs. An understanding of drug mode-of-action (MoA) would aid the develop-
ment of these new drugs, but our knowledge of how the current antitrypanosomals work is
lacking [1]. This has also been the case for drugs currently in clinical trials and for other prom-
ising compounds that emerged from phenotypic cell-based screening campaigns. These gaps
in knowledge will only become more acute given the current trend of phenotypic screening
and the typically high attrition rate during the development of compounds that emerge from
target-based screening [1].
In the case of Human African Trypanosomiasis (HAT), there are five current drugs, and
two in clinical trials [1]. The disease progresses from stage 1 to stage 2, when parasites invade
the central nervous system, which is typically lethal without treatment. The current drugs are
eflornithine, melarsoprol, nifurtimox, pentamidine and suramin. Nifurtimox and eflornithine
were introduced most recently and are used in combination to treat stage 2 disease in West
Africa [3]; eflornithine, however, is particularly challenging to administer. Melarsoprol use has
been largely phased out, as it is highly toxic [4]. Resistance to melarsoprol, due to the disrup-
tion of a parasite aquaglyceroporin [5,6,7], is also now widespread, but this drug remains the
only available treatment for stage 2 disease in East Africa; the parasite sub-species found in this
region is not susceptible to eflornithine [8]. Pentamidine and suramin are used to treat stage 1
disease in West and East Africa, respectively. The new orally active drugs in clinical trials are
acoziborole / SCYX-7158 [9] and fexinidazole [10].
With the exception of eflornithine and acoziborole, the mechanisms of action for the anti-
trypanosomal drugs above are not understood in any detail. Eflornithine enters trypanosomes
via the amino-acid transporter AAT6 [11] and inhibits ornithine decarboxylase [12] and, only
recently, acoziborole was shown to target an mRNA maturation factor known as CPSF3 [13].
Almost all antitrypanosomal drugs emerged based on an ability to selectively target trypano-
somes or to reduce parasite viability in cell culture or in animal models. Rather than differ-
ences between host and parasite intracellular targets, the selective efficacy of suramin,
melarsoprol and pentamidine is at least partly due to trypanosome-specific uptake mecha-
nisms [14]. Suramin enters trypanosomes via an endocytic pathway involving a bloodstream
stage-specific invariant surface glycoprotein ISG75 [14], and variant surface glycoprotein [15].
The action of suramin is enhanced by the import of ornithine, via an amino acid transporter
[16], and its metabolism by ornithine decarboxylase, such that eflornithine is antagonistic [14].
Drug mode-of-action in T. brucei
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Suramin inhibits pyruvate kinase in vitro but the drug may also occupy ADP/ATP binding
sites in other enzymes [17], none of which have been validated as targets in vivo. Melarsoprol
is an arsenical drug that enters trypanosomes via an adenosine transporter [18] and an aqua-
glyceroporin, AQP2 [5], acting primarily by forming a stable adduct, known as Mel T, with the
antioxidant, trypanothione [19]. Pentamidine, like melarsoprol, enters trypanosomes via
AQP2 [5]. Indeed, pentamidine inhibits the glycerol permeability of AQP2 [20] but this partic-
ular activity has little impact on parasite viability. Rather, this DNA-binding drug [21]
becomes highly concentrated in the cell and collapses trypanosome mitochondrial membrane
potential [22]. Pentamidine remains a low nanomolar antitrypanosomal agent against para-
sites lacking mitochondrial (kinetoplast) DNA, however, which display only 2.5-fold resistance
[23,24]. Nifurtimox and fexinidazole are both nitro pro-drugs that are activated by a putative
ubiquinone nitroreductase (NTR) located in parasite mitochondria [14,25,26], but it is
unknown whether these drugs kill parasites primarily by disrupting mitochondrial functions
or whether the toxic metabolites access targets outside the mitochondria.
Cytology-based profiling can facilitate antibiotic discovery efforts [27] and a selection of
cellular assays have been previously applied to antitrypanosomal compounds [28]; but this pre-
vious study examined only one of the current HAT compounds (pentamidine) and employed
only two of the assays described below. We now report cytology-based profiling for T. brucei
to probe the MoA of all five antitrypanosomals used in patients. We describe a panel of assays
that assess cell cycle progression, nuclear and mitochondrial DNA content, mitochondrial
DNA replication, nuclear DNA damage, mitochondrial membrane potential, and lysosome
structure and function. Using these assays, we show that each drug tested induces specific and
distinct cellular perturbations, yielding novel insight into the MoA of the antitrypanosomal
agents. Follow-up studies revealed a melarsoprol-induced mitotic defect that is dependent
upon a specific set of kinases.
Results
T. brucei growth profiles during exposure to antitrypanosomal drugs
The potency of the antitrypanosomal drugs used in the clinic varies widely. The 50% effective
growth inhibitory concentration (EC50) determined against bloodstream-form T. brucei in cul-
ture is in the low nM range for pentamidine (2.5 nM), suramin (27 nM) and melarsoprol (7
nM) but is in the low μM range for eflornithine (15 μM) and nifurtimox (2.6 μM); a 6,000-fold
differential between the most potent (pentamidine) and least potent (eflornithine). It is impor-
tant to note that, since EC50 values are typically determined over three to four days, they may
fail to reflect the rate at which growth is inhibited or whether the compound is cytocidal or
cytostatic at a particular concentration.
We examined the growth profiles of bloodstream-form trypanosomes treated with each of
the five clinical antitrypanosomal drugs at 1 x EC50 and 5 x EC50; see Materials and methods.
All drugs had a relatively moderate impact on growth at 1 x EC50, as expected (Fig 1). In con-
trast, growth at 5 x EC50 revealed a clear difference between eflornithine, which is known to be
cytostatic [29], and the other drugs, which were all demonstrably cytocidal over four days (Fig
1). We selected 5 x EC50 exposure for 24 hours for subsequent assays. These concentrations
and this time-point were selected to achieve a balance between allowing robust primary phe-
notypes to develop but to minimise the emergence of secondary effects associated with loss of
viability.
Our first cellular assay was a simple examination of each of the five populations of drug-
treated cells for defects in gross cellular morphology by phase-contrast microscopy. We found
that the majority of suramin-treated cells became enlarged and distorted (see below). We also
Drug mode-of-action in T. brucei
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looked for the ‘BigEye’ phenotype, which is associated with an endocytosis-defect and
observed following treatment with the N-myristoyltransferase inhibitor DDD85646 [30], how-
ever this phenotype was not seen.
Melarsoprol inhibits mitosis and suramin inhibits cytokinesis
Arguably the simplest and most widely used fluorescent-staining method for T. brucei is
DAPI-staining of DNA followed by microscopy. This is particularly informative for T. brucei
because cells in which the single mitochondrial genome, or kinetoplast, has segregated are eas-
ily visualised and scored, alongside the unsegregated or segregated nuclear genome [31]. We,
therefore, examined DAPI-stained cells by microscopy following drug-exposure. Cells were
scored according to the number of nuclei (n) and kinetoplasts (k). In non-treated cells (Fig 2A,
NT), we found that ~80% of cells displayed a 1n1k pattern (primarily G1 + S-phase), ~15% of
cells were 1n2k (primarily G2) and ~5% of cells were 2n2k (post-mitosis). We exercised some
caution when analysing these data for drug-treated cells, and focused on only robust pheno-
types that preceded or were coincident with loss-of-viability. The analysis revealed a major
increase in the proportion of cells with more than two nuclei following suramin treatment
(79%), while eflornithine treatment also yielded an appreciable increase, with 11% of cells hav-
ing more than two nuclei (Fig 2A, yellow bars). In addition, we noted ~5% of cells lacking a
kinetoplast (0k) following pentamidine treatment (Fig 2A, orange bar, see below). This loss of
kinetoplast DNA is consistent with previous observations [28].
DNA staining followed by flow cytometry allows the rapid analysis of large numbers of cells
and can reveal relative cellular (primarily nuclear) DNA-content. Accordingly, we next
Fig 1. T. brucei growth profiles during exposure to antitrypanosomal drugs. Parasites were treated with each of the five clinical
antitrypanosomals at 1 x EC50 and 5 x EC50 concentration. Cells that are not treated (NT) are shown as controls. Data are averages
of four technical replicates. Error bars show standard deviation.
https://doi.org/10.1371/journal.pntd.0006980.g001
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examined propidium iodide stained cells by flow cytometry following drug-exposure. Untreated
cells showed the characteristic profile, with a G2/M population that was approximately half the
magnitude of the G1 population (Fig 2B, top-left and red profiles). In this assay, both nifurti-
mox-treated and pentamidine-treated cells conformed to the profile observed for untreated
cells. In contrast, and consistent with the microscopy analysis above, we observed >70% of cells
with>2n DNA content following suramin treatment; eflornithine treatment also yielded an
appreciable increase in this category (Fig 2B, blue profiles). Only melarsoprol treatment yielded
a second, distinct and notable perturbation using this assay; the G2/M population increased
from 51% to 83%, relative to the G1-population (Fig 2B, blue profile). Since we had not scored
an increase in the proportion of 2n cells by microscopy following melarsoprol-treatment, this
particular flow-cytometry profile indicated an increase in cells with a replicated but unsegre-
gated nuclear genome. Thus, DNA-staining with microscopy and flow cytometry suggested that
suramin inhibited cytokinesis and that melarsoprol inhibited mitosis (see below).
DNA replication in kinetoplasts and DNA damage in nuclei
The TUNEL (Terminal deoxynucleotidyl transferase dUTP Nick End Labelling) assay allows
the fluorescent labelling and detection of blunt DNA ends, following programmed cell-death
Fig 2. Cell cycle distribution of trypanosomes following drug treatment. (A) Cell cycle distribution was determined
by DAPI staining and microscopy. NT, not treated; Efl, eflornithine; Mel, melarsoprol; Nif, nifurtimox; Pen,
pentamidine; Sur, suramin. All drug treatments were at 5 x EC50 for 24 h. ‘n’ and ‘k’ refer to the number of nuclei and
kinetoplasts in each cell; error bars, SD; N = 2. (B) Cell cycle distribution was determined by flow cytometry. Top left
panel shows the gates used to calculate cell cycle stage. Other details as in A.
https://doi.org/10.1371/journal.pntd.0006980.g002
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(PCD) for example; notably, conventional PCD is not thought to operate in trypanosomatids
[32]. Using this assay, TUNEL-signals were not readily detected in trypanosome nuclei. In
contrast, and as previously reported [33], we observed robust signals associated with kineto-
plasts (Fig 3A). We found approximately 25% of control cells to be TUNEL-positive (Fig 3A).
Eflornithine, nifurtimox and melarsoprol-treatment did not significantly alter the proportion
of cells with detectable TUNEL-signals when compared to cells that had not been exposed to
drug (Fig 3A), but the proportions of TUNEL-positive cells were significantly reduced follow-
ing pentamidine or suramin-treatment (Fig 3A). This was likely due to loss of kinetoplast
DNA following pentamidine-treatment (see above) and may have been due to limited repeated
rounds of kinetoplast DNA replication in multi-nucleated cells following suramin-treatment
(see below).
TUNEL signals were found to be cell cycle dependent (Fig 3B), consistent with the high
concentration of transient nicked DNA ends expected to be present during the replication of
thousands of minicircles [34]. Indeed, the majority (91%) of elongated kinetoplasts (in S-phase
cells) and a substantial proportion (22%) of segregated kinetoplasts (in G2 cells) were TUNEL-
positive, while we observed very few TUNEL-positive kinetoplasts in G1 or post-mitotic cells
(Fig 3C). The TUNEL-signals were consistently observed at opposite poles of extended kineto-
plasts and, when present, on both segregated kinetoplasts. Notably, the appearance of kineto-
plast-associated TUNEL-signals remained synchronised even in those suramin-treated cells
with four kinetoplasts; all four were either negative or positive in each cell (Fig 3D). Thus,
TUNEL revealed those cells that are progressing through kinetoplast S-phase and indicated
continued synchronisation, even in cells with four kinetoplasts.
We previously identified trypanosome γH2A, a modified histone H2A that is phosphory-
lated at the C-terminus and that accumulates at sites of nuclear DNA double-strand breaks
[35]. To assess nuclear DNA damage in drug-treated cells, we used a γH2A antibody in an
immunofluorescence assay; methyl methanesulfonate (MMS) is a radiomimetic DNA-damag-
ing agent and was included as a positive control (Fig 3E). We found no significant differences
in the proportion of cells with nuclear γH2A foci compared to untreated cells (Fig 3E), suggest-
ing that none of the current drugs kill trypanosomes by forming double-strand breaks in
nuclear DNA. Notably, the nitro pro-drugs, nifurtimox and fexinidazole, although found to be
mutagenic by Ames test (Salmonella typhimurium based assay), are not thought to be geno-
toxic to mammalian cells [36,37].
Both nifurtimox and pentamidine disrupt mitochondrial membrane
potential
MitoTracker fluorescence staining is dependent upon mitochondrial membrane potential. We
treated trypanosomes with antitrypanosomal drugs and scored cells by microscopy for an
extended MitoTracker signal, as observed in non-treated cells (Fig 4A, NT panels). Signifi-
cantly fewer cells scored positive for extended signals following either nifurtimox or pentami-
dine-treatment, compared to non-treated cells (Fig 4A). There were also qualitative differences
in signals resulting from drug treatments; whereas pentamidine eliminated the detectable sig-
nal, nifurtimox-treatment produced an intense and discreet signal adjacent to the kinetoplast
(Fig 4A). Notably, mitochondrial membrane potential was maintained following suramin-
treatment (Fig 4A), despite the gross morphological perturbations observed in these cells.
LysoTracker is highly selective for acidic organelles. We treated trypanosomes with antitry-
panosomal drugs and scored cells for LysoTracker signals by microscopy. Non-treated cells
displayed a single signal between the nucleus and kinetoplast (~60%), as expected for the try-
panosome lysosome (Fig 4B, NT panels). Melarsoprol substantially reduced the proportion of
Drug mode-of-action in T. brucei
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LysoTracker-positive cells (Fig 4B), but this failed to achieve statistical significance. In the case
of suramin, which is known to accumulate in trypanosomes through receptor-mediated endo-
cytosis [14], acidification of the lysosomal compartment does not appear to be perturbed (Fig
4B). The variability we observe in this assay suggests either that additional replicates will be
desirable in future, or that this particular assay will be of value only when major lysosomal per-
turbation occurs.
Pentamidine induces progressive loss of kinetoplast DNA
Using the DAPI, TUNEL and MitoTracker assays following pentamidine-treatment, we
observed kinetoplast-loss, a reduced proportion of positive cells and a loss of mitochondrial
membrane potential, respectively. To quantify these effects, we scored each phenotype
Fig 3. Assessment of ‘DNA-breaks’ in nuclei and gaps in kinetoplast circles. (A) Percentage of cells positive for a
TUNEL signal. ���, P< 0.001 from Students t-test. The microscopy images show an example of the kinetoplast-
associated TUNEL signal in NT cells. (B) Example images of TUNEL signals, always associated with the kinetoplast (k)
rather than the nucleus (n), at different cell cycle stages; G1, S, G2 and post M (post mitotic). Dashed boxes indicate
magnified regions shown in C. (C) Percentage of cells in each cycle stage positive for TUNEL signals, inset images
show magnified signals from B as indicated by dashed boxes. (D) Examples of TUNEL signals in none or all four
kinetoplasts following suramin treatment. (E) Percentage of cells positive for γH2A signals. The microscopy images
show an example of the nuclear γH2A signal in NT cells. MMS, methyl methanesulfonate. Other details in A, C and E
as in Fig 2A; error bars, SD; N = 2; all scale bars, 5 μm.
https://doi.org/10.1371/journal.pntd.0006980.g003
Drug mode-of-action in T. brucei
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following 12, 24, and 48 h of drug-exposure (Fig 5A–5C). These analyses revealed a sharp
increase in kinetoplast-negative cells in the 48-h DAPI-stained population (Fig 5A) and a pro-
gressive decline in TUNEL-positive (Fig 5B) and MitoTracker-positive cells (Fig 5C) at each
time-point.
DAPI-stained cells appeared to reveal progressively diminished kinetoplast DNA rather
than loss in one step. For a quantitative and objective assessment of kinetoplast DNA-staining
intensity, we adapted an ImageJ-based approach [31]; see Materials and methods. ImageJ effi-
ciently identified nuclei and kinetoplasts in untreated cells (Fig 5D, red and green, respectively
in the upper panel), but failed to identify very low-intensity kinetoplasts in pentamidine-
treated cells (Fig 5D, open green circle in the lower panel). A quantitative analysis indicated
that the kinetoplasts that are still detected following pentamidine-treatment display reduced
surface area and signal intensity relative to the control population; values are expressed relative
to nuclei in the same cell (Fig 5D). These results confirm progressive loss of kinetoplast DNA
induced by pentamidine.
Nifurtimox induces a specific reduction in mitochondrial protein
abundance
Nifurtimox-treatment produced an intense and discreet MitoTracker signal adjacent to the
kinetoplast (Fig 4A). To explore this effect further, we stained the nuclear-encoded F1β-sub-
unit of the mitochondrial ATP-synthase (Tb927.3.1380) in drug-treated and MitoTracker-
stained cells and examined these cells by microscopy. The ATP-synthase signal was largely
coincident with the extended MitoTracker signal in control cells (Fig 6A, NT panels) and was
Fig 4. Assessment of mitochondrial and lysosomal phenotypes. (A) The microscopy images show examples of the
Mitotracker signals. Percentage of cells positive for the typical ‘extended’ Mitotracker signal are shown. �, P< 0.05
from Students t-test. (B) The microscopy images show examples of the Lysotracker signals observed in untreated and
suramin-treated cells. Percentage of cells positive for Lysotracker signal are shown. Other details as in Fig 2A; error
bars, SD; N = 2; scale bars, 5 μm except for suramin-treated cells, which are 10 μm.
https://doi.org/10.1371/journal.pntd.0006980.g004
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also coincident with the focal MitoTracker signal in nifurtimox-treated cells (Fig 6A, Nif pan-
els), possibly indicating a structural defect in mitochondria in the latter cells. We next assessed
F1β-subunit expression by protein blotting of whole-cell extracts, which revealed a substantial
and specific reduction in abundance following nifurtimox-treatment (Fig 6B). Depletion of
the ATP-synthase component may reflect a more widespread depletion of mitochondrial pro-
teins, consistent with activation of this pro-drug by a mitochondrial NTR [14,25,26]. Using the
same assays, pentamidine-treated cells displayed a diffuse and cytosolic, rather than mitochon-
drial, ATP-synthase signal (Fig 6A, Pen panels). In this case, protein import into mitochondria
[38] may be defective as a result of loss of mitochondrial membrane potential, as indicated by
the diminished MitoTracker signal (Fig 6A, Pen panels). Consistent with this hypothesis, the
total cellular F1β signal detected by protein blotting remained constant following pentamidine
treatment (Fig 6B).
Melarsoprol inhibits mitosis by a mechanism that is suppressed by multiple
kinases
DNA staining followed by microscopy or flow cytometry suggested that melarsoprol inhibited
mitosis. Indeed, a closer inspection of DAPI-stained cells revealed a sub-set (>10%) with “con-
joined” nuclei (Fig 7; top panels, double-arrowheads). For an objective assessment of nuclear
DNA-staining intensity in these cells, we used the quantitative ImageJ-based approach; see
Materials and methods. In this case, nuclei were compared to kinetoplasts in ‘1n2k’ cells,
Fig 5. Pentamidine induces progressive loss of kinetoplast DNA. Effects of pentamidine treatment for 12, 24 and 48
h on (A) percentage of kinetoplast negative cells, (B) percentage of TUNEL-positive cells and (C) percentage of
extended Mitotracker signal positive cells. The inset in A shows an example of a cell with no detectable kinetoplast
DNA; error bars, SD; N = 2; scale bar, 5μm. (D) ImageJ analysis. Raw images (left hand panels) and ImageJ outputs
(right hand panels) demonstrating that kinetoplasts fall below the threshold of detection (open green circle). Ratios of
kinetoplasts to nuclei, total area and total signal (area multiplied by mean intensity) are plotted for cells with detectable
kinetoplasts. Red lines, averages; ���, P< 0.001 from Students t-test.
https://doi.org/10.1371/journal.pntd.0006980.g005
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revealing both increased nuclear surface area and signal intensity following melarsoprol-treat-
ment (Fig 7). These quantitative results confirmed the mitotic defect resulting from melarso-
prol treatment.
Cytology-based profiling may be combined with orthogonal approaches to probe antitrypa-
nosomal compound MoA. We have found high-throughput genetic screening to be particu-
larly informative [13,14]. A prior RNA interference (RNAi) Target Sequencing (RIT-seq)
screen revealed a highly significant (P = 2.3 × 10−9) over-representation of kinases, comprising
three hits among the top seven in this screen; these were a putative mitogen-activated protein
kinase (MAPK11, Tb927.10.12040), a putative MAPK kinase (MKK4, Tb927.8.5950) and a
putative MAPK kinase kinase (STE11, Tb927.10.1910) [14]. It is also notable that trypanosome
CDC14 (Tb927.11.12430) was a hit in this screen, since human Cdc14 stabilises Wee1, a key
Fig 6. Nifurtimox induces a specific reduction in mitochondrial protein abundance. (A) The microscopy images
show the Mitotracker signals and F1β mitochondrial ATP-synthase subunit following nifurtimox or pentamidine
treatment. Scale bar, 5 μm. (B) Protein blotting to detect the F1β mitochondrial ATP-synthase subunit following
nifurtimox or pentamidine treatment; predicted size, 55.8 kDa.
https://doi.org/10.1371/journal.pntd.0006980.g006
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kinase that inhibits mitosis [39]. Thus, knockdowns that promote mitosis may partially coun-
teract the inhibitory effects of melarsoprol, but the RIT-seq screening hits noted above have
not previously been independently validated nor further characterised. To explore our
Fig 7. Quantitative analysis of the melarsoprol-induced mitotic defect. (A) ImageJ analysis. Raw images (left hand
panels) and ImageJ outputs (right hand panels) demonstrating conjoined nuclei (red arrowheads) after melarsoprol
treatment. (B) DNA content of nuclei in melarsoprol (Mel) treated and non-treated (NT) cells is plotted. Ratio of area
and signal (area multiplied by average intensity) of nuclei to average area and signal of kinetoplasts in ‘1n2k’ cells.
Error bars, SD; red lines, averages; ���, P< 0.001 from Students t-test.
https://doi.org/10.1371/journal.pntd.0006980.g007
Drug mode-of-action in T. brucei
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hypothesis, we further characterised these kinases. All three were expressed with a C-terminal
12-myc epitope tag and the tagged proteins were all found to localise to the trypanosome cyto-
sol (Fig 8A). Since RIT-seq screening fails to yield clonal knockdown strains [14], we assem-
bled pairs of independent knockdown strains for two of the kinases (Tb927.10.12040 and
Tb927.8.5950). Both knockdowns, confirmed by monitoring the epitope-tagged proteins (Fig
8B), reproducibly and significantly (P< 0.0001) increased melarsoprol EC50 by 1.7 +/- 0.07
fold and 1.5 +/- 0.01 fold, respectively (Fig 8C), as predicted by the RIT-seq screen [14].
Finally, we determined whether knockdown alleviated the melarsoprol-induced, conjoined-
nuclei phenotype and found that this was indeed the case for both kinases (Fig 8D). Thus, the
melarsoprol-induced mitotic defect is kinase-dependent.
Discussion
Cytocidal or cytostatic compounds identified using phenotypic approaches may target pro-
teins, nucleic acids, membranes or other metabolites. They may also exhibit polypharmacol-
ogy, killing cells by perturbing multiple pathways. Even compounds developed as target-based
therapies may kill trypanosomes by ‘off-target’ mechanisms. Determining mechanism of
action remains a major challenge for these drugs and compounds and an improved under-
standing of how they kill parasites could present new opportunities in terms of developing
more potent compounds, delivering compounds to their targets more effectively or devising
combination therapies that minimise the likelihood of resistance. Eflornithine kills trypano-
somes by inhibiting ornithine decarboxylase but the mode-of-action of the other four current
antitrypanosomal drugs is not known. Our studies indicate that cytology-based profiling can
provide a rapid and effective means to yield insight into drug mode-of-action and we now
present additional insights into the mode-of-action for all current drugs used to treat human
African trypanosomiasis.
Suramin was found to produce cells with more than two nuclei, indicating a defect in cyto-
kinesis with continued mitosis. Multi-nucleated cells were still stained by MitoTracker, indi-
cating that this organelle retained membrane potential. DAPI-staining and TUNEL (terminal
dUTP nick end labelling) assays indicated that nuclear:nuclear and nuclear:kinetoplast replica-
tion remained synchronised in these cells. Indeed, although the TUNEL assay failed to reveal
any nuclear DNA damage induced by the drugs used here, it did provide an excellent marker
for the kinetoplast replication cycle, producing robust signals consistent with the presence of
DNA-ends at antipodal sites on the kinetoplast during minicircle DNA replication [34]. In this
regard, TUNEL provides a useful marker for kinetoplast S-phase.
Pentamidine is a DNA-binding drug [21] that collapses trypanosome mitochondrial mem-
brane potential [22] and induces loss of kinetoplast DNA [28]. Data from Saccharomyces cere-
visiae indicated pentamidine accumulation in the mitochondrion but also inhibition of
translation in these cells [40]. In addition, metabolomic studies indicated that pentamidine is
unlikely to act through the inhibition of any specific metabolic pathways [41]. We find that
pentamidine-induced loss of kinetoplast DNA is progressive, suggesting progressive loss of
maxi- and minicircles; the latter are present in thousands of copies per kinetoplast [34]. Kinet-
oplast DNA loss is revealed by both DAPI-staining and TUNEL-assay. Loss of kinetoplast
DNA is expected to disrupt membrane-potential since the A6-subunit of the ATP-synthase,
required to maintain this potential, is encoded by kinetoplast DNA [42]. Thus, we suggest that
kinetoplast DNA is indeed a primary target for pentamidine, involving inhibition of mito-
chondrial type II topoisomerase action, as previously suggested [43]. What remains unclear is
whether loss of mitochondrial membrane-potential is solely a consequence of the kinetoplast
defect or whether this reflects an independent response to pentamidine.
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Nifurtimox is a pro-drug that is activated by a mitochondrial NTR [26], but it is unknown
whether the toxic metabolite(s) access(es) targets outside the mitochondrion, or whether para-
site killing is primarily due to disruption of mitochondrial functions. We found that nifurti-
mox, like pentamidine, also disrupted the MitoTracker signal. Kinetoplast defects were not
observed, however, and the MitoTracker staining pattern was distinct to that seen with pent-
amidine. Nifurtimox also induced loss of a nuclear-encoded ATP-synthase subunit, while data
from pentamidine-treated cells indicated that ATP-synthase was still expressed, but not
imported, when membrane potential was perturbed. Thus, we suggest severe disruption of
mitochondrial structure and function by nifurtimox, consistent with damage to targets in the
organelle where the drug is activated. Fexinidazole is another nitro pro-drug, currently in clin-
ical trials, that is also activated by mitochondrial NTR [25]. These drugs may act through simi-
lar antitrypanosomal mechanisms.
Melarsoprol forms potentially toxic adducts with trypanothione [19], and we now show
that this drug increases the proportion of cells with a replicated but unsegregated nuclear
genome. This indicates a defect in mitosis. The identification of multiple putative kinases in a
loss-of-function screen for melarsoprol-resistance suggested a role for a signalling cascade in
melarsoprol susceptibility [14]. The current findings led us to consider a more specific role for
these putative kinases in the control of mitosis. Indeed, these proteins are putative MAPK,
MAPKK and MAPKKKs and our results now indicate that the mitotic defect is less
Fig 8. Melarsoprol inhibits mitosis by a kinase-dependent mechanism. (A) The microscopy images show the localisation of three C-terminal epitope (myc)
tagged kinases. Scale bar, 5 μm. (B) Protein blotting indicates tetracycline (Tet)-inducible RNAi-mediated knockdown of the indicated kinases. Coomassie-stained
gels serve as loading-controls. (C) Dose-response curves for melarsoprol following knockdown (+Tet) of the indicated kinases. EC50 values are shown +/- SD. Data
are shown for pairs of biological replicates; similar data were also obtained for a third biological replicate in each case. (D) The melarsoprol-induced conjoined
nuclei phenotype is diminished following knockdown of the indicated kinases. �, P< 0.05 from Students t-test.
https://doi.org/10.1371/journal.pntd.0006980.g008
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pronounced when the putative MAPK (Tb927.10.12040) and MAPKK (Tb927.8.5950) are
depleted. We suggest that these kinases negatively control mitosis, as part of normal quality
control following DNA replication. Bypass of this surveillance could allow cells to continue to
grow, possibly accumulating, but tolerating, melarsoprol-induced (oxidative) damage. Thus,
knockdowns that promote mitosis may partially counteract the inhibitory effects of
melarsoprol.
Arsenicals are used to treat leukemia but are also themselves mutagens. There is indeed evi-
dence that arsenic induces DNA damage in yeast [44]. Notably, the MoA in yeast involves acti-
vation of a MAP kinase pathway [45] and this also appears to be the case in mammalian cells
[46], where mitotic arrest occurs as a result of induction of a mitotic spindle checkpoint [47].
We did not detect any evidence for nuclear DNA damage in T. brucei following melarsoprol
treatment but, as detailed above, did find a melarsoprol-dependent and kinase-dependent
mitotic defect. Thus, arsenical MoA may operate through a common kinase signalling cascade
leading to mitotic arrest in both trypanosomes and mammalian cells. Notably, like the Myt1
kinase, which phosphorylates Cdc2 and controls mitosis in Xenopus [48], Tb927.10.1910 has a
putative transmembrane domain; Tb927.10.1910 also has a putative guanylate cyclase domain.
These findings illustrate how cytology and genetic approaches can converge to yield insights
into drug MoA in trypanosomes. In this case, we propose a common MoA for arsenicals in
human cells and in trypanosomes.
Cytology-based approaches can provide rapid and cost-effective methods for quantitative
profiling of cellular responses to drugs. The drugs can also be considered as chemical probes
for exploring parasite biology. Taking a systematic cytology-based approach with antitrypano-
somal drugs of uncertain MoA, our findings indicate target organelles and structures for pent-
amidine, nifurtimox and melarsoprol; the kinetoplast, the mitochondrion and the nucleus,
respectively. Further analysis, guided by the primary assays, indicated destruction of mito-
chondrial ATP-synthase by nifurtimox and a mitotic defect induced by melarsoprol. These
assays should also provide novel insights into MoA when applied to cells treated with other
antitrypanosomal compounds, including those with known primary targets. Common profiles
will allow compounds to be clustered based on their primary MoA. New assays and bespoke
assays can be incorporated as appropriate and these may be guided by outputs from orthogo-
nal genetic, proteomic, metabolomic or computational approaches. The approach may also be
usefully applied to the other parasitic trypanosomatids, T. cruzi and Leishmania. These and
other approaches should reveal those particularly susceptible pathways that can be prioritised
and targeted by antitrypanosomal therapies.
Materials and methods
Strains and drugs
Lister 427 derived T. brucei (clone 221a) bloodstream form cells were grown in HMI-11 in the
presence of antitrypanosomal drugs. Cultures were initiated at 2 x 105 cells.ml-1 and incubated
at 37˚C in a humidified 5% CO2 atmosphere. The drugs were applied at five times the EC50, as
determined using a standard AlamarBlue assay [49]; for EC50 determination, drug exposure
was for 66–67 h and AlamarBlue incubation was for 5–6 h. Plates were read on an Infinite 200
Pro plate-reader (Tecan). The EC50 values of the antitrypanosomal drugs used were: Eflor-
nithine 15 μM; Melarsoprol 7 nM; Nifurtimox 2.6 μM; Pentamidine 2.5 nM; Suramin 27 nM.
Methyl methanesulfonate (MMS, Sigma) was used at 0.0003%. To monitor cumulative try-
panosome growth, cultures were grown in the presence of drug, with four technical replicates
of cell density counted at 6, 9, 24, 48, 72 and 96 h. Cultures were diluted with fresh media con-
taining the appropriate drug, such that cell density never exceeded 2 x 106 cells.ml-1. All
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tagging and RNAi constructs were transfected into 2T1 T. brucei cells [50]. RNAi was induced
with tetracycline (1 μg/ml) for three days prior to initiating EC50 determination.
Microscopy
Cells were grown in the presence of drug at 5 x EC50 for 24 h, unless stated otherwise. Cells
were then fixed in 2% v/v paraformaldehyde for 30 min at 4˚C before being washed three
times in PBS. Fixed cells were dried onto slides before staining with antibodies (outlined
below). Slides were washed in PBS and mounted in Vectashield containing DAPI (Vector Lab-
oratories); 4, 6-diamidino-2-phenylindole. Scoring of phenotypes was carried out by counting
100 cells per condition, and by two of us, with the data combined. For immunofluorescence
analysis (IFA), cells dried onto slides were permeablised in 0.5% Triton X100 / PBS for 20 min
and washed three times in PBS before blocking in 50% foetal bovine serum FBS / PBS. Primary
antibody (α-γH2A) [35] was diluted 1:250 and applied for 1 h, slides were washed three times
in PBS, and secondary antibody (fluorescein-conjugated goat anti-rabbit) was diluted 1:100
and then applied for 1 h. Antibodies were applied in 3% FBS / PBS. The F1β-subunit of the
mitochondrial ATP-synthase was similarly detected using a polyclonal rabbit antiserum
directed against the Crithidia fasciculata ATP synthase (1:500), which cross-reacts with the T.
brucei orthologue [51,52]. All phase and epifluorescence images were captured on an Eclipse
E600 microscope (Nikon) using a Coolsnap FX (Photometrics) charged coupled device camera
and processed in Metamorph 5.4 (Photometrics).
MitoTracker assay
MitoTrackerRed (Invitrogen) was added to cultures at 100 nM. Cultures were incubated for 5
min under standard conditions before parasites were harvested by centrifugation at 1000 x g
for 10 min before fixing as outlined above.
LysoTracker assay
LysoTracker (Invitrogen) was added to cultures at 50 nM. Cultures were incubated under stan-
dard conditions for 1 h before parasites were harvested by centrifugation at 1000 x g for 10
min before fixing as outlined above.
TUNEL assay
Cells on slides were fixed, dried and permeablised as described above for IFA. Reaction mix
from the ‘In Situ Cell Death Detection Kit (fluorescein)’ (Roche) was applied to cells for 1 h as
per the manufacturer’s instructions.
Flow cytometry
Cells were harvested and washed in ice cold PBS and resuspended in 300 μl PBS before the
addition of 700 μl of methanol and stored at 4˚C for 12 h. Cells were then harvested at 400 x g
for 10 min at 4˚C and resuspended in 1 ml PBS. 10 μg/ml RNAse A and 10 μg/ml propidium
iodide was added to each sample and incubated at 37˚C for 45 min in the dark. Analysis was
performed on an LSRII flow cytometer (BD Biosciences), and data analysis was conducted in
FlowJo (Tree Star).
ImageJ analysis
All images of DAPI fluorescence were captured at 40 ms exposure time for consistency and to
avoid overexposure. They were analysed using an ImageJ plug-in [31] modified to enable cell
Drug mode-of-action in T. brucei
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006980 November 26, 2018 15 / 19
cycle analysis from DAPI and phase contrast images. DAPI alone was suitable for the identifi-
cation of nuclei and kinetoplasts, since kinetoplasts do not generally overlap with nuclear
DNA signals in bloodstream form T. brucei. As in the original ImageJ plug-in, two kinetoplasts
are counted only when no longer linked by pixels with signal. A subset of the original macros
were retained and modified, as necessary: Measure K/N Signal, Cell Analysis, K/N Count Sum-
mary, and Save Analysis. First, the Measure K/N Signal tool thresholds images using built-in
ImageJ functions, and extracts object area values from DAPI images. Next, the script applies
the K-means clustering algorithm [31] to separate kinetoplasts and nuclei into respective clus-
ters, returning values for the maximum kinetoplast area and minimum nucleus area. These
values are then passed to the Cell Analysis tool which finds objects in phase images, creates
binary copies of the phase and DAPI image and identifies kinetoplasts and nuclei, counting
how many lie within each cell. K/N Count Summary and Save Analysis tools function identi-
cally to the original macros described in [31]. Macro scripts are available on request.
Plasmid construction
For tagging native Tb927.8.5950, Tb927.10.12040 and Tb927.10.1910 alleles with 12-myc epi-
tope tags at the C-terminus, we used the following primer-pairs, to amplify 893, 1038 and 769
bp fragments, respectively: 5950MF (GATCAAGCTTGATCCATGTGTAGTTGAC) and
5950MR (GATCTCTAGAGGATACTGGTGAACCATC); 12040MF (GATCAAGCTTGGCA
CACTTTCACCACGAT) and 12040MR (GATCTCTAGACTCAACGGAACCCACATATT);
1910MF (GATCAAGCTTGCGTGTATCTAGGCATGGA) and 1910MR (GATCTCTAGAA
AGGGAAAAAAGTG). These primer-pairs incorporate HindIII and XbaI sites, respectively
(italics). The resulting fragments were cloned in the pNATx12MYC construct [53]. The resulting
pNAT5950-12myc, pNAT12040-12myc and pNAT1910-12myc constructs were linearized by digestion
with Bstz171, EcoRV and EcoRV prior to transfection, respectively. For knockdown of Tb92
7.8.5950 or Tb927.10.12040 using RNA interference, we used the following primer-pairs,
respectively: 5950RF2 (GATCTCTAGAGGATCCAAACGACCCAAGTTGGAGAG) and
5950RR2 (GATCGGGCCCGGTACCGCTTCCAGCGTCCATGTATT); 12040RF2 (GATCTC
TAGAGGATCCATTCTTGGTGAGTTGCTGGG) and 12040RR2 (GATCGGGCCCGGTACC
ACTCTCATCATACACCGCCC). These primer-pairs incorporate XbaI / BamHI and ApaI /
KpnI sites, respectively (italics). The resulting fragments were cloned in the pRPaiSL construct
[53]. The resulting pRPa5950-RNAi and pRPa12040-RNAi constructs were linearized by digestion
with AscI prior to transfection.
Protein blotting
Total cell extracts were separated on SDS-polyacrylamide gels and subjected to standard western
blotting analysis. Duplicate gels were generated and one was stained with Coomassie and the
other was used to produce the nitrocellulose blot. Blots were blocked in 5% milk in TBST and
washes were performed in TBST (0.05% Tween). Blots were then probed with mouse α-c-Myc
primary antibody (1:5000; 9E10, Source Biosciences) or the ATP synthase primary antibody
(1:500). Following incubation with the appropriate secondary antibodies (1:2000; Pierce), mem-
brane was washed and visualised using the Amersham enchanced chemiluminescence (ECL)
detection system (GE Healthcare Life Sciences) according to the manufacturer instructions.
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